UNASSIGNED: 2062 Background: Treatment of @entity3 ( @entity15053 ) remains challenging due to advanced @entity262 at presentation and limited treatment options. METHODS: All @entity1 underwent standard pre-treatment @entity15053 assessment including @entity2841 assessment (cytology or flow cytometry), brain and spine MR imaging, and radioisotope @entity2841 flow study. Liposomal @entity2592 was administered intraventricularly (n=80) or intralumbar (n=40) at 50mg every 2-weeks x4 and then every 4-weeks x6 in responding @entity1 . @entity619 (4mg orally twice per day x5days) was co-administered with each liposomal @entity2592 treatment. @entity1 were seen with each liposomal @entity2592 treatment and assessed for @entity137 . RESULTS: 120 adult @entity1 (median age 51 years [range 33-68]) with @entity15053 were treated with liposomal @entity2592 . Liposomal @entity2592 Common @entity137 Criteria > Grade 3 @entity2359 was seen in 62 cycles (11.9%) in 28 @entity1 (23.3%). @entity137 included @entity4008 (3.75% ventricular: 0% lumbar); @entity693 (17.5%:15%); communicating @entity1276 (3.75%: 5%); conus medullaris/ @entity1971 (5%:5%); decreased visual acuity (5%:2.5%); @entity75 (5%: 5%); @entity62 (7.5%: 2.5%); @entity602 (2.5%: 2.5%); @entity614 (1.25%: 5%); and @entity410 (1.25%: 2.5%). Distribution of @entity137 was similar regardless of route of administration (ventricular vs. lumbar). @entity137 were transient in 38 episodes (61.3%) and permanent in 24 (38.7%; 17 @entity1 ). There were no treatment-related deaths however 20 treatment-related @entity137 (32.2%) required hospitalization. CONCLUSIONS: Liposomal @entity2592 is mostly well tolerated however a subset of @entity1 (14%) not easily identified pre-treatment develop serious treatment-related @entity16 that may be persistent and impact quality of life.

XXXX of intra- @entity2841 liposomal @entity2592 in the treatment of leptomeningeal metastases.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity', 'toxicities', 'Toxicities', 'toxicity'] @entity4008 :: ('MESH:D016920', 'Disease') :: ['bacterial meningitis'] @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus'] @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy'] @entity15053 :: ('MESH:C537267', 'Disease') :: ['LMD'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications'] @entity602 :: ('MESH:D013118', 'Disease') :: ['myelopathy'] @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity693 :: ('MESH:D008581', 'Disease') :: ['chemical meningitis'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone'] @entity3 :: ('MESH:D009362', 'Disease') :: ['leptomeningeal metastasis'] @entity1971 :: ('MESH:D011128', 'Disease') :: ['cauda equina syndrome'] @entity62 :: ('MESH:D056784', 'Disease') :: ['leukoencephalopathy'] @entity614 :: ('MESH:D011843', 'Disease') :: ['radiculopathy'] @entity2841 :: ('1437', 'Gene') :: ['CSF'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity']
@entity2359 :: (MESH:D020258,Disease) :: ['Neurotoxicity']
